Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis
August 04, 2022 08:00 ET
|
Arcutis Biotherapeutics, Inc.
A total of 654 adults and children, age six and older, have been enrolled in the INTEGUMENT-1 trialEnrollment continues in INTEGUMENT-2 with topline data from both trials expected by end of 2022Atopic...
Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer
July 18, 2022 06:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007
July 06, 2022 00:40 ET
|
HUTCHMED (China) Limited
SAN DIEGO and SHANGHAI and HONG KONG and SYDNEY, Australia, July 06, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;...
CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
May 12, 2022 10:47 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 12 by Evelo Biosciences, Inc. (Nasdaq: EVLO), please note that in the first sentence...
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of PH-10 Immuno-Dermatology Agent for Treatment of Inflammatory Dermatoses and Epithelial Diseases
May 03, 2022 06:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, May 03, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent (USP) application 16/204,832,...
Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors
April 21, 2022 06:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
Evelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation Programs
April 14, 2022 06:00 ET
|
Evelo Biosciences, Inc.
–Guidance on registration trials for EDP1815 in psoriasis expected in 3Q 2022––Data from initial cohort of patients in Phase 2 trial of EDP1815 in atopic dermatitis expected 1Q 2023––Faster release...
European Dermatology Excimer Laser Industry to 2027 - Key Drivers and Challenges
April 14, 2022 05:43 ET
|
Research and Markets
Dublin, April 14, 2022 (GLOBE NEWSWIRE) -- The "Europe Dermatology Excimer Laser Market By Product, By Application, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027" report has...
Evelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of Directors
April 06, 2022 06:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing Cream
December 13, 2021 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Data presented at Revolutionizing Atopic Dermatitis (RAD) ConferenceVehicle tested was comparable to the moisturizing cream based on primary endpoint of change in transepidermal water loss (TEWL) from...